Loading
HS
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Stock: price and insider trades · China
*ST双成
Hainan Shuangcheng Pharmaceuticals Co., Ltd.: what insiders have been doing
This page follows insider dealings at Hainan Shuangcheng Pharmaceuticals Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. 3 insiders have disclosed 5 filings since 18 October 2025.
No insider bought on the market over the period, while 3 insiders filed 5 sales totalling €430k. The largest single trade was a sale of €138k by Li Jianming, published on 13 October 2026.
Most trades are made public on the day they happen. That lag is the time during which only the insider knows about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 533 companies) published 2 filings over the same period, against 5 filings here. Our records for Hainan Shuangcheng Pharmaceuticals Co., Ltd. go back to 2022, with no purchases and 8 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Insider Decl.
8
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€681,269
8 ops. · all time
Who traded when
BuySaleLi Jianming2 sales
姚忠2 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,810 of 24,161 companies
41.7
score / 100
Value25
Quality58
FCF yld0.5%
Earn yld0.5%
EV/EBITDA57.9x
ROE10.0%
Gross mgn55%
Net mgn6.9%
Debt/EBITDA3.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥9.73
Analyst consensus
Income statement
RevenueCN¥276.8M
Gross profitCN¥151.5M55% margin
EBITDACN¥70.8M26% margin
Net incomeCN¥19M16.5% margin
Valuation
PER (trailing)74.8x
P/Book9.5x
Beta0.52
Balance sheet & cash
Market capCN¥4B
Total debtCN¥213.7M
Free Cash FlowCN¥17.7M
Debt / Equity63%
Profitability & ownership
ROE10.0%
ROA4.0%
% insiders53.3%
% institutions0.1%
Last declaration on 22 September 2026
Declarations8 total
40,000 shares@ CN¥72.920128.7% of flowA股XSHESZSE:273000001580814700
100,000 shares@ CN¥72.275371.3% of flowA股XSHESZSE:273000001575619420
10,000 shares5.7% of flowA股XSHESZSE:173000006004796900
240,000 shares94.3% of flowA股XSHESZSE:173000005937704350
8 of 8 declarations
About Hainan Shuangcheng Pharmaceuticals Co., Ltd.
*ST双成 is a company listed on the XSHE market, specializing in the healthcare and pharmaceutical sector. It focuses on the development and production of innovative drugs and treatments.
